(RTTNews) - Moderna, Inc (MRNA) shares suffered their steepest decline since August after leaked late-stage trial results for its personalized melanoma vaccine showed a smaller risk reduction than an earlier study.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。